---
layout: post
title: "Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability"
date: 2026-02-04 21:48:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-14233
original_published: 2025-07-29 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

**Published:** February 04, 2026 21:48 UTC
**Source:** Federal Register
**Original Published:** July 29, 2025 00:00 UTC
**Document Number:** 2025-14233

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Regeneron Pharmaceuticals, Inc. (Regeneron) for REGEN-COV (casirivimab and imdevimab administered together), to GlaxoSmithKline LLC (GSK) for sotrovimab, to Eli Lilly and Company (Lilly) for bebtelovimab, and to AstraZeneca Pharmaceuticals LP (AstraZeneca) for EVUSHELD (tixagevimab co-packaged with cilgavimab). FDA revoked these Authorizations on December 13, 2024, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, including an explanation of the reasons for the revocations, are reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/07/29/2025-14233/revocation-of-emergency-use-of-a-drug-product-during-the-covid-19-pandemic-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-14233

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
